Document:

Exhibit 10.17

 

RESEARCH AGREEMENT

 

THIS AGREEMENT, effective on the 1st day of October 2021, is
between SunHydrogen, Inc., a for-profit corporation (“Sponsor”) and the REGENTS OF THE UNIVERSITY OF MICHIGAN, a non-profit
educational institution of the State of Michigan (“University”).

 

WHEREAS, the research program contemplated by this Agreement
is of mutual interest and benefit to University and to Sponsor, will further the instructional and research objectives of University in
a manner consistent with its status as a non-profit, tax-exempt, educational institution, and may derive benefits for both Sponsor and
University through inventions, improvements, or discoveries; and

 

WHEREAS, Sponsor understands and accepts that research by its
nature is to explore, examine, and test ideas, hypothesis and/or theories and the outcome of a research effort is inherently uncertain.

 

NOW, THEREFORE, in consideration of the above assumptions and
the promises and mutual covenants below, the parties agree to the following:

 

ARTICLE 1 - DEFINITIONS

 

1.1 “Project” means the research project described in ORSP
22-PAF00982 under the direction of Nirala Singh as Principal Investigator entitled “Manufacturing
Science to Increase Efficiency of Photoelectrosynthetically Active Heterostructures for H2 Production.”

 

1.2 “Contract Period” is from October 1, 2021, through September
30, 2022, unless earlier terminated pursuant to this Agreement.

 

1.3 “Intellectual Property” means Joint Intellectual Property,
Sponsor Intellectual Property, and University Intellectual Property.

 

1.4 “Joint Intellectual Property” means individually and
collectively all inventions, improvements or discoveries which are made jointly as defined in U.S. Patent law by one or more employees
of Sponsor and one or more employees of University in performance of the Project during Contract Period.

 

1.5 “Sponsor Intellectual Property” means any and all inventions,
improvements or discoveries which are conceived or made solely as defined by U.S. Patent law by one or more employees of Sponsor.

 

1.6 “University Intellectual Property” means any and all
inventions, improvements or discoveries which are conceived or made solely as defined by U.S. Patent law by one or more employees of University
in performance of the Project during Contract Period.

 

    Page 1 of 8

     

    

 

1.7 “Commercial Sales” refer to the first Sale, rental,
or lease by Sponsor or Sponsor’s Sublicensee of Licensed Product or Licensed Process.

 

1.8 “Patent Rights” means University’s legal rights
under the patent laws of the United States or relevant foreign countries for all of the University’s interest in University Intellectual
Property and/or Joint Intellectual Property.

 

1.9 “Sale” means sale, rental, or lease, however characterized,
and Sold means the past tense of SALE.

 

1.91 “Sublicensee(s)” means any person or entity in writing
sublicensed, or granted an option for a sublicense, by Sponsor or another Sublicensee under this Agreement.

 

1.92 “Licensed Process(es)” means any process or method
that, but for this Agreement, comprises an infringement of (including contributory or inducement), or is covered by, an issued, unexpired
claim or a pending claim contained in the Patent Rights or employs a Licensed Product.

 

1.93 “Licensed Product(s)” means any product that: (a)
but for this Agreement comprises an infringement of (including contributory or inducement), or is covered by, an issued, unexpired claim
or a pending claim contained in the Patent Rights in the country in which any such product or product part is made, used, imported, offered
for Sale or Sold; or (b) is manufactured by using a Licensed Process or is employed to practice a Licensed Process.

 

ARTICLE 2 - RESEARCH WORK

 

2.1 University and Sponsor will use reasonable efforts to perform the
Project substantially in accordance with the terms and conditions of this Agreement.

 

2.2 In the event that the Principal Investigator becomes unable or
unwilling to continue Project, and a mutually acceptable substitute is not available, University or Sponsor has the option to terminate
the Project.

 

ARTICLE 3 - REPORTS AND CONFERENCES

 

3.1 University will periodically provide written program reports to
Sponsor. The University will submit a final report at the conclusion of the Contract Period.

 

3.2 During the Contract Period, representatives of the University may
meet with representatives of Sponsor at times and places mutually agreed upon to discuss the progress and results as well as ongoing plans,
or changes in the Project.

 

    Page 2 of 8

     

    

 

ARTICLE 4 - COSTS, BILLINGS, AND OTHER SUPPORT

 

4.1 Total costs to Sponsor will not exceed Two Hundred Ninety Six Thousand,
Four Hundred Forty Eight Dollars ( $296,448) which shall be paid by Sponsor in equal quarterly installments during the Contract Period.
Payment will be made by Sponsor within 30 days of receipt of an invoice. Notice of any dispute regarding the charges in an invoice must
be provided in accordance with Article 16 and include a description of the item(s) in dispute and a reasonably detailed explanation of
the reason for the dispute. Sponsor will be billed monthly for actual charges incurred by the University. Any dispute regarding the charges
in the final invoice must be made within 90 days after receipt.

 

4.2 University will retain title to any equipment purchased with funds
provided by Sponsor under this Agreement.

 

4.3 In the event of early termination of the Project by Sponsor, Sponsor
will pay all costs accrued by University as of the date of termination, including non-cancelable obligations, such as non-cancelable contracts
and fellowships or postdoctoral associate appointments called for in Project. Any obligation of Sponsor for fellowships or postdoctoral
associates end no later than the end of University’s academic year during which termination occurs.

 

ARTICLE 5 - PUBLICITY

 

Sponsor will not use the name of University, nor of any member of University’s
Project staff, in any advertising, news release or other promotional activity without the prior written approval of an authorized representative
of University, which approval shall not be unreasonably withheld. University will not use the name of Sponsor, nor any employee of Sponsor,
in any advertising or other promotional activity without the prior written approval of Sponsor. Both parties retain any right to disclose
the existence of this Agreement, the identity of the parties, or the nature and scope of the Project. University understands that Sponsor
is subject to the reporting requirements of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and shall
not be prohibited from making any required disclosure with respect to this Agreement in compliance with the Exchange Act and the regulations
promulgated thereunder, including the filing of this Agreement with the Securities and Exchange Commission.

 

ARTICLE 6 - PUBLICATIONS

 

6.1 Subject to the following terms, the University has the right to
publish, publicly present, or otherwise make available to the public the results, analysis, and methods relating to the University Project
(a “Disclosure of Results”). The University will notify Sponsor at least twenty (20) days in advance of the earlier of either
(a) the submission to a third party, such as a journal, of a proposed publication or public presentation that would include a Disclosure
of Results or (b) other public Disclosure of the Results, and furnish a description of the content therein.

 

6.2 If the content would contain either (a) patentable subject matter
that is Intellectual Property of any party under Article 7 or (b) Confidential Information disclosed pursuant to Article 15, then Sponsor
has the right to object in writing to the Disclosure of the Results within twenty (20) days after the University furnishes such description.
If Sponsor makes a timely objection under clause 6.2(a) and concurrently makes a direction under Section 7.2 below, then University will
refrain from the Disclosure of the Results until the University files patent application in accordance with Section 7.2 or sixty days
from the date of the objection, whichever is earlier. If Sponsor makes a timely objection under clause 6.2(b), then University will comply
with Sponsor’s reasonable request to delete or modify information that is Confidential Information, giving due recognition to University’s
missions and interests in publishing the result of University projects.

 

    Page 3 of 8

     

    

 

ARTICLE 7 - INTELLECTUAL PROPERTY

 

7.1 All rights and title to University Intellectual Property are owned
by University. All rights and title to Joint Intellectual Property are jointly owned by Sponsor and University. All rights and title to
Sponsor Intellectual Property are owned by Sponsor.

 

7.2 Each party will notify the other party if it becomes aware of any
potentially patentable University Intellectual Property or Joint Intellectual Property, and provide a description thereof. If Sponsor
so directs University within thirty (30) days after such notification, then (a) University will promptly prepare, file, and prosecute
a U.S. and any appropriate foreign application(s) covering the University Intellectual Property or Joint Intellectual Property (“Patents”)
and (b) Sponsor will promptly reimburse University for all reasonable fees and costs relating to such activities.

 

7.3 University has the right to control all aspects of filing, prosecuting,
and maintaining the Patents. University will furnish to Sponsor copies of all papers received from or filed with governmental patent offices
in connection with the prosecution of Patents in sufficient time for Sponsor to comment upon them. Sponsor will hold such information
confidential and to use the information provided by University only for the purpose of advancing University’s rights in the Patents.
Sponsor will cooperate with University to assure that such Patents will cover, to the best of Sponsor’s knowledge, all items of commercial
interest and importance, which will include keeping University apprised of Sponsor’s relevant products in commerce and development.

 

7.4 Sponsor may elect to discontinue or refrain from reimbursing University
for fees and costs relating to any given patent or application within the Patents. If Sponsor discontinues, refrains, or fails to promptly
reimburse University for all fees and costs relating to a given patent or application, then University may elect to continue the prosecution
and/or maintenance of such patent or application at University’s sole expense and all Sponsor’s ownership and option rights
in the applicable patents or patent applications shall be and are hereby terminated and transferred to the University, without the need
for additional documentation.

 

    Page 4 of 8

     

    

 

ARTICLE 8 - GRANT OF RIGHTS

 

8.1 University does and shall hereby grant Sponsor a royalty-free,
non-exclusive, non-sublicensable license to use University Intellectual Property for internal research and development purposes.

 

8.2 A) Provided that Sponsor has fulfilled its obligations under Section
7.2 above, University does and shall hereby grant to Sponsor a world-wide, exclusive, freely sub-licensable license to the Patent Rights
to make, have made, import, use, market, offer for Sale and sell Licensed Products and to practice Licensed Processes. In exchange for
this grant, Sponsor agrees to pay University a nonrefundable technology fee as follows:

 

i) Upfront technology fee in the amount of $15,000 within thirty (30)
days of receipt of an invoice.

ii) $100,000 upon first commercial use resulting in Commercial Sales.

 

8.2 (B) If Sponsor stops supporting the legal and official fees for
a particular licensed patent, design or application thereof within the University Foreground IP, and the University assumes the financial
and other responsibilities for that patent, design or application, then Sponsor’s license under 8.2(A) is and shall be terminated. If
Sponsor fails to make payment pursuant to section 8.2(A) the grant in Section 8.2(A) shall be and is hereby terminated without the need
for additional documentation.

 

8.3 In the event that Sponsor acquires an exclusive license or right
under this Agreement,

University specifically reserves the right for it and its affiliates
to practice and have practiced the University Intellectual Property or Joint Intellectual Property, for research, public service, internal
(including clinical) and/or educational purposes, and the right to grant the same limited rights to other non-profit research institutions.

 

8.4 The licenses granted in this Agreement are subject to any rights
required to be granted under prior research or sponsorship agreements, or retained by the U.S. government, for example in accordance with
Chapter 18 of Title 35 of U.S.C. 200-212 and the regulations thereunder (37 CFR Part 401), when applicable. Sponsor agrees to comply in
all respects, and shall provide University with all reasonably requested information and cooperation for University to comply with applicable
provisions of the same and any requirements of any agreements between University and any agency of the U.S. government that provided funding
for the subject matter covered by the University Intellectual Property or Joint Intellectual Property.

 

ARTICLE 9 - TERM AND TERMINATION

 

9.1 This Agreement is effective upon the date first written above and
continues in effect for the full duration of the Contract Period. The parties may extend the term of this Agreement for additional periods
under mutually agreeable terms and conditions which the parties reduce to writing and sign. Either party may terminate this agreement
upon ninety days prior written notice to the other.

 

9.2 If either party breaches or defaults on any of the terms or conditions
of this Agreement, and fails to remedy the default or breach within ninety days after receipt of written notice of it from the other party,
the party giving notice may, at its option and in addition to any other remedies which it may have at law or in equity, terminate this
Agreement by sending notice of termination in writing to the other party. The termination shall be effective as of the date of the receipt
of the notice or 3 days after sending, whichever occurs first.

 

9.3 No termination of this Agreement, however effectuated, shall release
the parties from their rights and obligations accrued prior to the effective date of termination.

 

    Page 5 of 8

     

    

 

ARTICLE 10 - INDEPENDENT CONTRACTOR

 

10.1 Under this Agreement the University’s relation to Sponsor
is solely that of an independent contractor and neither party’s employees are entitled to any benefits applicable to employees of
the other;

 

10.2 Neither party is authorized or empowered to act as agent for the
other for any purpose and may not on behalf of the other enter into any contract, warranty or representation on any matter. Neither shall
be bound by the acts or conduct of the other.

 

ARTICLE 11 - INSURANCE AND INDEMNIFICATION

 

11.1 University warrants and represents that University has adequate
liability insurance applicable to officers, employees, and agents while acting within the scope of their employment by University. University
liability insurance policies do not extend protection to any other person.

 

11.2 Each party assumes all risks of personal injury and property damage
attributable to the negligent acts or omissions of its own officers, employees, and agents.

 

11.3 Sponsor understands that the University is an educational institution
created under Article 8, Section 5 of the State of Michigan Constitution of 1963. The University, as a state institution, has strict limitations
imposed upon its use of assets and consequently the University does not and cannot pay for any claims against Sponsor brought by third
parties related to this Agreement.

 

ARTICLE 12 - GOVERNING LAW

 

This Agreement shall be governed and construed in accordance with the
laws of the State of Michigan without regard for principles of choice of law. Any claims, demands, or actions arising from this Agreement
shall be brought in the state of Michigan. Sponsor, its successors and assigns, consent to the jurisdiction of a court with applicable
subject matter jurisdiction sitting in the state of Michigan with respect to any claims arising under this agreement.

 

ARTICLE 13 - ASSIGNMENT

 

13.1 Except as provided in Section 13.2, this Agreement may not be
assigned by either party without the prior written consent of the other.

 

13.2 This Agreement is assignable to any division of Sponsor, any majority
stockholder of Sponsor, or any legally controlled subsidiary of Sponsor.

 

ARTICLE 14 - AGREEMENT MODIFICATION

 

Any agreement to change the terms of this Agreement in any way shall
be valid only if the change is made in writing and signed by authorized representatives of the parties hereto.

 

    Page 6 of 8

     

    

 

ARTICLE 15 - CONFIDENTIALITY

 

15.1 University agrees to use confidential or proprietary information
and data acquired from Sponsor and identified as confidential or proprietary at the time of disclosure (“Confidential Information”)
only in performing the services of this Agreement and not to disclose to any third party any Confidential Information during and for a
period of five (5) years from the date of disclosure provided that if Confidential Information is disclosed orally or in other non-tangible
form, Sponsor will supply the University in writing a general description of the Confidential Information and confirmation of its confidential
or proprietary status within twenty (20) working days of disclosure.

 

15.2 The obligation to protect Confidential Information shall not apply
to any information that: (1) is already in the possession of, or is independently developed by, University; (2) becomes publicly available
other than through breach of this provision; (3) is received by University from a third party with authorization to make the disclosure;
(4) is released with Sponsor’s written consent; or (5) is required to be released by legal process or other legal authority provided that,
to the extent permitted by law, University shall notify Sponsor in writing of such disclosure and University shall take reasonable and
lawful steps to facilitate any legal process initiated by Sponsor in connection with any protective order or remedy sought by Sponsor
in connection with such order.

 

ARTICLE 16 - NOTICES

 

Any notice to either party must be in writing, signed by the party
giving it, and served to the addresses below (or to such other addressee as may be later designated by written notice) by personal delivery,
recognized overnight courier service with package tracking, or by the United States mail, first-class, certified or registered, postage
prepaid, return receipt requested. All notices are effective when received or within three days of sending, whichever occurs first.

 

	If to Sponsor:	 	 
	 	 	Attn: Woosuk Kim
	 	 	10 E. Yanonali St, suite 36 
	 	 	 
	 	 	Santa Barbara, CA 
	93101	                                	 	 
	 	 	 	 
	wkim@sunhydrogen.com ________________________
	 	 	 	 
	If to University:	 	University of Michigan
	 	 	 	Office of Research and Sponsored Projects
	 	 	3003 S. State St.,
	 	 	Ann Arbor, MI 48109-1274
	 	 	Attn: Kate Chie

 

    Page 7 of 8

     

    

 

ARTICLE 17 – SEVERABILITY

 

The terms of this Agreement are severable. If any term or provision
is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of the provisions shall continue
to be valid and enforceable.

 

ARTICLE 18 – WAIVER

 

Unless a specific time limitation is specified, no delay or omission
by either party to exercise any right or remedy under this Agreement shall be construed to be either acquiescence or the waiver of the
ability to exercise any right or remedy in the future.

 

ARTICLE 19 – NO THIRD PARTY RIGHTS

 

Nothing in this Agreement shall be construed as creating or giving
rise to any rights in third parties or persons other than the named parties to this Agreement.

 

ARTICLE 20 – EXECUTION

 

This Agreement may be signed in several originals, which together constitute
a single Agreement. The parties agree that a signature on any one of the originals and delivered by facsimile or email are valid, binding
and enforceable. The parties acknowledge and agree that this Agreement has been mutually discussed, negotiated, drafted by the parties
and no provision may be interpreted adversely to a party as a presumed drafter.

 

ARTICLE 21 – SURVIVEABILILTY

 

Provisions surviving termination or expiration of this Agreement are
those which on their face affect rights and obligations after termination or expiration, including provisions concerning indemnification,
confidentiality, warranty and choice of law and venue.

 

AGREED TO:

 

	 	 	THE REGENTS OF THE UNIVERSITY
	SunHydrogen, Inc.	 	OF MICHIGAN
	 	 	 
	By	 /s/ Woosuk Kim	 	By	 /s/ Peter J. Gerard
	 	 	 
	Typed Name Woosuk Kim	 	Typed Name Peter J. Gerard
	 	 	 
	Title Chief Operating Officer	 	Title Asst. Director--Sponsored Programs

 

 

Page 8 of 8Exhibit 4.4

 

WARRANT AGREEMENT

 

ARBOR RAPHA CAPITAL BIOHOLDINGS CORP. I

and

CONTINENTAL STOCK TRANSFER & TRUST COMPANY

 

Dated [●], 2021

 

THIS WARRANT AGREEMENT (this “Agreement”),
dated [●], 2021, is by and between Arbor Rapha Capital Bioholdings Corp. I, a Delaware corporation (the “Company”),
and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (in such capacity, the
 “Warrant Agent”).

 

WHEREAS, it is proposed that the Company enter
into that certain Private Placement Warrants Purchase Agreement with Arbor Rapha Capital LLC, a Delaware limited liability company (the
 “Sponsor”), pursuant to which the Sponsor will purchase an aggregate of 3,833,333 warrants (or up to 4,133,333
warrants depending on the extent to which the underwriters in the Offering (defined below) exercise their Over-allotment Option (as defined
below)) in full, simultaneously with the closing of the Offering (and the closing of the Over-allotment Option, if applicable), bearing
the legend set forth in Exhibit B hereto (the “Private Placement Warrants”) at a purchase price of $1.50
per Private Placement Warrant. Each Private Placement Warrant entitles the holder thereof to purchase one share of Common Stock (as defined
below) at an exercise price of $11.50 per share, subject to adjustment as described herein; and

 

WHEREAS, in order to fund the trust account in
connection with the Company’s initial public offering, the Sponsor has agreed to loan to the Company $3,750,000 (or $4,312,500
if the underwriter’s over-allotment is exercised in full), which may be convertible into warrants, such warrants bearing the legend
set forth in Exhibit B hereto (“Sponsor Loan Warrants”), at a purchase price of $1.50 per warrant; and

 

WHEREAS, in order to finance the Company’s
transaction costs in connection with an intended initial merger, capital stock exchange, asset acquisition, stock purchase, reorganization
or similar business combination, involving the Company and one or more businesses (a “Business Combination”),
the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan
the Company funds as the Company may require, of which up to $1,500,000 of such loans may be convertible into up to an additional 1,000,000
Private Placement Warrants at a price of $1.50 per Private Placement Warrant; and

 

WHEREAS, the Company is engaged in an initial
public offering (the “Offering”) of units of the Company’s equity securities, each such unit
comprised of one share of Common Stock and one third of one Public Warrant (as defined below) (the
 “Units”) and, in connection therewith, has determined to issue and deliver up to 5,750,000 redeemable
warrants (including up to 750,000 redeemable warrants subject to the extent of the exercise of the Over-allotment Option) to public
investors in the Offering (the “Public Warrants” and, together with the Private Placement Warrants and the Sponsor Loan Warrants, the
 “Warrants”). Each whole Warrant entitles the holder thereof to purchase one share of Class A common stock
of the Company, par value $0.0001 per share (“Common Stock”), for $11.50 per share, subject to adjustment
as described herein. Only whole Warrants are exercisable. A holder of the Public Warrants will not be able to exercise any fraction
of a Warrant; and

 

     

     

    

 

WHEREAS, the Company has filed with the Securities
and Exchange Commission (the “Commission”) a registration statement on Form S-1, File No. 333-[●] (the
 “Registration Statement”) and a prospectus (the “Prospectus”), for the registration,
under the Securities Act of 1933, as amended (the “Securities Act”), of the Units, the Public Warrants and the
Common Stock included in the Units; and

 

WHEREAS, the Company desires the Warrant Agent
to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer,
exchange, redemption and exercise of the Warrants; and

 

WHEREAS, the Company desires to provide for the
form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of
rights, and immunities of the Company, the Warrant Agent and the holders of the Warrants; and

 

WHEREAS, all acts and things have been done and
performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant
Agent (if a physical certificate is issued), as provided herein, the valid, binding and legal obligations of the Company, and to authorize
the execution and delivery of this Agreement.

 

NOW, THEREFORE, in consideration of the mutual
agreements herein contained, the parties hereto agree as follows:

 

1.            
Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the
Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions
set forth in this Agreement.

 

2.            
Warrants.

 

2.1             
Form of Warrant. Each Warrant shall initially be issued in registered form only.

 

2.2             
Effect of Countersignature. If a physical certificate is issued, unless and until countersigned by the Warrant Agent pursuant
to this Agreement, a certificated Warrant shall be invalid and of no effect and may not be exercised by the holder thereof.

 

2.3             
Registration.

 

2.3.1       
Warrant Register. The Warrant Agent shall maintain books (the “Warrant Register”), for the registration
of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants in book-entry form, the
Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise
in accordance with instructions delivered to the Warrant Agent by the Company. Ownership of beneficial interests in the Public Warrants
shall be shown on, and the transfer of such ownership shall be effected through, records maintained by institutions that have accounts
with The Depository Trust Company (the “Depositary”) (such institution, with respect to a Warrant in its account,
a “Participant”).

 

    2

     

    

 

If the Depositary subsequently ceases to make its
book-entry settlement system available for the Public Warrants, the Company may instruct the Warrant Agent regarding making other arrangements
for book-entry settlement. In the event that the Public Warrants are not eligible for, or it is no longer necessary to have the Public
Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depositary to deliver to the Warrant
Agent for cancellation each book-entry Public Warrant, and the Company shall instruct the Warrant Agent to deliver to the Depositary definitive
certificates in physical form evidencing such Warrants (“Definitive Warrant Certificates”) which shall be in
the form annexed hereto as Exhibit A.

 

Physical certificates, if issued, shall be signed
by, or bear the facsimile signature of, the Chairman of the Board, Chief Executive Officer, Chief Financial Officer or other principal
officer of the Company. In the event the person whose facsimile signature has been placed upon any Warrant shall have ceased to serve
in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he
or she had not ceased to be such at the date of issuance.

 

2.3.2       
Registered Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent
may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”)
as the absolute owner of such Warrant and of each Warrant represented thereby, for the purpose of any exercise thereof, and for all other
purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

2.4             
Detachability of Warrants. The shares of Common Stock and Public Warrants comprising the Units shall begin separate trading
on the 52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday,
on which banks in New York City are generally open for normal business (a “Business Day”), then on the immediately
succeeding Business Day following such date, or earlier (the “Detachment Date”) with the consent of Cantor Fitzgerald
 & Co., but in no event shall the shares of Common Stock and the Public Warrants comprising the Units be separately traded until (A)
the Company has filed a Current Report on Form 8-K with the Commission containing an audited balance sheet reflecting the receipt by the
Company of the gross proceeds of the Offering, including the proceeds then received by the Company from the exercise by the underwriters
of their right to purchase additional Units in the Offering (the “Over-allotment Option”), if the Over-allotment
Option is exercised prior to the filing of the Current Report on Form 8-K, and (B) if the Detachment Date is earlier than the 52nd day
following the date of the Prospectus, the Company issues a press release announcing when such separate trading shall begin.

 

2.5             
Fractional Warrants. The Company shall not issue fractional Warrants other than as part of the Units, each of which is comprised
of one share of Common Stock and one third of one whole Public Warrant. If, upon the detachment of Public Warrants from the Units or otherwise,
a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down to the nearest whole number the number
of Warrants to be issued to such holder.

 

    3

     

    

 

2.6               Private
Placement Warrants and Sponsor Loan Warrants. The Private Placement Warrants and Sponsor Loan Warrants shall be identical to the Public Warrants, except that (i) the Private Placement Warrants and Sponsor Loan Warrants may be exercised
for cash or on a “cashless basis,” pursuant to subsection 3.3.1(c) hereof, (ii) the Private Placement Warrants
and Sponsor Loan Warrants (and shares of Common Stock issuable upon exercise of the Private Placement Warrants) and Sponsor Loan
Warrants may be subject to certain transfer restrictions contained in the letter agreement by and between the Company and each of
the Sponsor and other parties thereto, as may be amended from time to time, including that any permitted transferees must enter into
a written agreement with the Company agreeing to be bound by the transfer restrictions contained in such letter agreement, (iii) the
Private Placement Warrants and Sponsor Loan Warrants shall not be redeemable by the Company pursuant to Section 6.1
hereof and (iv) the holders of the Private Placement Warrants and Sponsor Loan Warrants (including the shares of Class A common
stock issuable upon exercise of such warrants) will be entitled to certain registration rights. The Private Placement Warrants and the Sponsor Loan Warrants shall not become Public Warrants as a result of any transfer of the Private
Placement Warrants or the Sponsor Loan Warrants and shall remain nonredeemable.

 

3.            
Terms and Exercise of Warrants.

 

3.1             
Warrant Price. Each whole Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant
and of this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $11.50 per share,
subject to the adjustments provided in Section 4 hereof and in the last sentence of this Section 3.1. The term “Warrant
Price” as used in this Agreement shall mean the price per share (including in cash or by payment of Warrants pursuant to
a “cashless exercise,” to the extent permitted or required hereunder) described in the prior sentence at which shares of Common
Stock may be purchased at the time a Warrant is exercised. The Company in its sole discretion may lower the Warrant Price at any time
prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days (unless otherwise required by
the Commission, any national securities exchange on which the Warrants are listed or applicable law); provided that the Company
shall provide at least three (3) days’ prior written notice of such reduction to Registered Holders of the Warrants and, provided
further that any such reduction shall be identical among all of the Warrants.

 

3.2              Duration
of Warrants. A Warrant may be exercised only during the period (the “Exercise Period”)
(A) commencing on the date that is the later of thirty (30) days after the first date on which the Company completes a Business
Combination or twelve (12) months from the closing of the Offering and (B) terminating at the earliest to occur of
(x) 5:00 p.m., New York City time on the date that is five (5) years after the date on which the Company completes its initial
Business Combination, (y) the liquidation of the Company in accordance with the Company’s amended and restated certificate of
incorporation, as amended from time to time, if the Company fails to complete a Business Combination, and (z) other than with
respect to the Private Placement Warrants and Sponsor Loan Warrants, 5:00 p.m., New York City time on the Redemption Date (as
defined below) as provided in Section 6.2 hereof (the “Expiration Date”); provided, however,
that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth in subsection
3.3.2 below, with respect to an effective registration statement or a valid exemption therefrom being available. Except with
respect to the right to receive the Redemption Price (as defined below) (other than with respect to a Private Placement Warrant  and
Sponsor Loan Warrants) in
the event of a redemption (as set forth in Section 6 hereof), each Warrant (other than a Private Placement Warrant and
Sponsor Loan Warrants in the event of a redemption) not exercised on or before the Expiration Date shall become void, and all rights
thereunder and all rights in respect thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration
Date. The Company in its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; provided that
the Company shall provide at least twenty (20) days’ prior written notice of any such extension to Registered Holders of the
Warrants and, provided further that any such extension shall be identical in duration among all the Warrants.

 

    4

     

    

 

3.3             
Exercise of Warrants.

 

3.3.1       
Payment. Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the Registered Holder
thereof by delivering to the Warrant Agent at its corporate trust department (i) the Definitive Warrant Certificate evidencing the
Warrants to be exercised, or, in the case of a Warrant represented by a book-entry, the Warrants to be exercised (the “Book-Entry
Warrants”) on the records of the Depositary to an account of the Warrant Agent at the Depositary designated for such
purposes in writing by the Warrant Agent to the Depositary from time to time, (ii) an election to purchase (“Election
to Purchase”) any shares of Common Stock pursuant to the exercise of a Warrant, properly completed and executed by the Registered
Holder on the reverse of the Definitive Warrant Certificate or, in the case of a Book-Entry Warrant, properly delivered by the Participant
in accordance with the Depositary’s procedures, and (iii) the payment in full of the Warrant Price for each share of Common Stock
as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange
of the Warrant for the shares of Common Stock and the issuance of such shares of Common Stock, as follows:

 

(a)           
in lawful money of the United States, in good certified check or wire payable to the Warrant Agent;

 

(b)           
in the event of a redemption pursuant to Section 6.1 hereof in which the Company’s board of directors (the “Board”)
has elected to require all holders of the Public Warrants to exercise such Public Warrants on a “cashless basis,” by surrendering
the Public Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number
of shares of Common Stock underlying the Public Warrants, multiplied by the difference between the Warrant Price and the “Fair Market
Value”, as defined in this subsection 3.3.1(b), by (y) the Fair Market Value. Solely for purposes of this subsection 3.3.1(b)
and Section 6.1, the “Fair Market Value” shall mean the volume-weighted average price of the shares of
Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the date on which the notice of redemption
is sent to the holders of the Warrants pursuant to Section 6.2 hereof;

 

(c)            with
respect to any Private Placement Warrant and Sponsor Loan Warrants, by surrendering the Warrants for that number of shares of Common Stock equal to the
quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the
excess of the “Sponsor Exercise Fair Market Value” (as defined in this subsection 3.3.1(c)) less the Warrant
Price by (y) the Sponsor Exercise Fair Market Value. Solely for purposes of this subsection 3.3.1(c), the
 “Sponsor Exercise Fair Market Value” shall mean the average last reported sale price of the shares of
Common Stock for the ten (10) trading days ending on the third (3rd) trading day prior to the date on which notice of
exercise of the Private Placement Warrant and Sponsor Loan Warrants is sent to the Warrant Agent; or

 

    5

     

    

 

(d)          
 as provided in Section 7.4 hereof.

 

3.3.2       
Issuance of Shares of Common Stock on Exercise. As soon as practicable after the exercise of any Warrant and the clearance
of the funds in payment of the Warrant Price (if payment is pursuant to subsection 3.3.1(a)), the Company shall issue to the Registered
Holder of such Warrant a book-entry position or certificate, as applicable, for the number of shares of Common Stock to which he, she
or it is entitled, registered in such name or names as may be directed by him, her or it on the share transfer books of the Company, and
if such Warrant shall not have been exercised in full, a new book-entry position or countersigned Warrant, as applicable, for the number
of shares as to which such Warrant shall not have been exercised. Notwithstanding the foregoing, the Company shall not be obligated to
deliver any shares of Common Stock pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise
unless a registration statement under the Securities Act with respect to the shares of Common Stock underlying the Public Warrants is
then effective and a prospectus relating thereto is current, or a valid exemption from registration is available. No Warrant shall be
exercisable and the Company shall not be obligated to issue shares of Common Stock upon exercise of a Warrant unless the shares of Common
Stock issuable upon such Warrant exercise have been registered, qualified or deemed to be exempt from registration or qualification under
the securities laws of the state of residence of the Registered Holder of the Warrants. For the avoidance of doubt, in no event will the
Company be required to net cash settle the Warrant exercise. Subject to Section 4.6 of this Agreement, a Registered Holder of Warrants
may exercise its Warrants only for a whole number of shares of Common Stock. The Company may require holders of Public Warrants to settle
their Public Warrants on a “cashless basis” pursuant to Section 7.4. If, by reason of any exercise of Warrants on a
 “cashless basis”, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional
interest in a share of Common Stock, the Company shall round down to the nearest whole number, the number of shares of Common Stock to
be issued to such holder.

 

3.3.3       
Valid Issuance. All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement
and the amended and restated certificate of incorporation, shall be validly issued, fully paid and nonassessable.

 

3.3.4       
Date of Issuance. Each person in whose name any book-entry position or certificate, as applicable, for shares of Common
Stock is issued shall for all purposes be deemed to have become the holder of record of such shares of Common Stock on the date on which
the Warrant, or book-entry position representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective
of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment
is a date when the share transfer books of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed
to have become the holder of such shares of Common Stock at the close of business on the next succeeding date on which the share transfer
books or book-entry system are open.

 

    6

     

    

 

3.3.5        Maximum
Percentage. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions
contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless
he, she or it makes such election. If the election is made by a holder, the Warrant Agent shall not effect the exercise of the
holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to
such exercise, such person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would
beneficially own in excess of 9.8% or such other amount as a holder may specify (the “Maximum Percentage”)
of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence,
the aggregate number of shares of Common Stock beneficially owned by such person and its affiliates shall include the number of
shares of Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made,
but shall exclude shares of Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of the
Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation,
any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the
limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership
shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, the holder may
rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Annual Report on Form
10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the Commission as the case may be, (2) a
more recent public announcement by the Company or (3) any other notice by the Company or Continental Stock Transfer & Trust
Company, as transfer agent (in such capacity, the “Transfer Agent”), setting forth the number of shares of
Common Stock outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall,
within two Business Days, confirm orally and in writing to such holder the number of shares of Common Stock then outstanding. In any
case, the number of issued and outstanding shares of Common Stock shall be determined after giving effect to the conversion or
exercise of equity securities of the Company by the holder and its affiliates since the date as of which such number of issued and
outstanding shares of Common Stock was reported. By written notice to the Company, the holder of a Warrant may from time to time
increase or decrease the Maximum Percentage applicable to such holder to any other percentage specified in such notice; provided, however,
that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the
Company.

 

4.            
Adjustments.

 

4.1             
Stock Dividends.

 

4.1.1        Split-Ups.
If after the date hereof, and subject to the provisions of Section 4.6 below, the number of issued and outstanding shares of
Common Stock is increased by a stock dividend of shares of Common Stock, or by a split-up of shares of Common Stock or other similar
event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable
on exercise of each Warrant shall be increased in proportion to such increase in the issued and outstanding shares of Common Stock.
A rights offering made to all holders of shares of Common Stock entitling holders to purchase shares of Common Stock at a price less
than the “Historical Fair Market Value” (as defined below) shall be deemed a stock dividend of a number of shares of
Common Stock equal to the product of (i) the number of shares of Common Stock actually sold in such rights offering (or issuable
under any other equity securities sold in such rights offering that are convertible into or exercisable for the shares of Common
Stock) multiplied by (ii) one (1) minus the quotient of (x) the price per share of Common Stock paid in such rights offering divided
by (y) the Historical Fair Market Value. For purposes of this subsection 4.1.1, (i) if the rights offering is for securities
convertible into or exercisable for shares of Common Stock, in determining the price payable for shares of Common Stock, there shall
be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or
conversion and (ii) “Historical Fair Market Value” means the volume-weighted average price of the shares
of Common Stock during the ten (10) trading day period ending on the trading day prior to the first date on which the shares of
Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. No
shares of Common Stock shall be issued at less than their par value.

 

    7

     

    

 

4.1.2       
Extraordinary Dividends. If the Company, at any time while the Warrants are outstanding and unexpired, pays to all holders
of Common Stock a dividend or make a distribution in cash, securities or other assets on account of such shares of Common Stock (or other
shares into which the Warrants are convertible), other than (a) as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends
(as defined below), (c) to satisfy the redemption rights of the holders of the Common Stock in connection with a proposed initial Business
Combination, (d) to satisfy the redemption rights of the holders of the Common Stock in connection with a stockholder vote to amend the
Company’s amended and restated certificate of incorporation (i) to modify the substance or timing of the Company’s obligation
to allow redemption in connection with the Company’s initial Business Combination or to redeem 100% of the Company’s public
shares if it does not complete its initial Business Combination within the time period required by the Company’s amended and restated
certificate of incorporation, as amended from time to time, or (ii) with respect to any other provision relating to stockholders’
rights or pre-initial Business Combination activity or (e) in connection with the redemption of public shares upon the failure of the
Company to complete its initial Business Combination and any subsequent distribution of its assets upon its liquidation (any such non-excluded
event being referred to herein as an “Extraordinary Dividend”), then the Warrant Price shall be decreased, effective
immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the fair market value (as determined
by the Board, in good faith) of any securities or other assets paid on each share of Common Stock in respect of such Extraordinary Dividend.
For purposes of this subsection 4.1.2, “Ordinary Cash Dividends” means any cash dividend or cash distribution
which, when combined on a per share basis, with the per share amounts of all other cash dividends and cash distributions paid on the shares
of Common Stock during the 365-day period ending on the date of declaration of such dividend or distribution to the extent it does not
exceed $0.50 (which amount shall be adjusted to appropriately reflect any of the events referred to in other subsections of this Section
4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number of shares
of Common Stock issuable on exercise of each Warrant).

 

4.2              Aggregation
of Shares. If after the date hereof, and subject to the provisions of Section 4.6 hereof, the number of issued and
outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares
of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split,
reclassification or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be decreased in
proportion to such decrease in issued and outstanding shares of Common Stock.

 

    8

     

    

 

4.3             
Adjustments in Exercise Price. Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants
is adjusted, as provided in subsection 4.1.1 or Section 4.2 above, the Warrant Price shall be adjusted (to the nearest cent)
by multiplying such Warrant Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of
shares of Common Stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of
which shall be the number of shares of Common Stock so purchasable immediately thereafter.

 

4.4             
Raising of the Capital in Connection with the Initial Business Combination. If (x) the Company issues additional shares
of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination
at an issue price or effective issue price of less than $9.20 per share of Common Stock (with such issue price or effective issue price
to be determined in good faith by the Board and, in the case of any such issuance to the Sponsor or its affiliates, without taking into
account any shares of Class B common stock, par value $0.0001 per share, of the Company held by the Sponsor or such affiliates, as applicable,
prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent
more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination
on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the volume-weighted average
price of the Common Stock during the twenty (20) trading day period starting on the trading day prior to the day on which the Company
consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the
Warrant Price shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price,
and the $18.00 per share redemption trigger price described in Section 6.1 shall be adjusted (to the nearest cent) to be equal
to 180% of the higher of the Market Value and the Newly Issued Price. If the adjustment in the immediately preceding sentence would otherwise
result in an increase in the Warrant Price (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations, Extraordinary
Dividends and similar events) hereunder, no adjustment shall be made.

 

    9

     

    

 

4.5              Replacement
of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the issued and outstanding shares
of Common Stock (other than a change under Section 4.1 or Section 4.2 hereof or that solely affects the par value of
such shares of Common Stock), or in the case of any merger or consolidation of the Company with or into another entity or conversion
of the Company into another type of entity (other than a merger or consolidation in which the Company is the continuing entity and
that does not result in any reclassification or reorganization of the issued and outstanding shares of Common Stock), or in the case
of any sale or conveyance to another corporation or entity of the assets or other property of the Company as an entirety or
substantially as an entirety in connection with which the Company is dissolved, the holders of the Warrants shall thereafter have
the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the
shares of Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented
thereby, the kind and amount of shares, stock or other equity securities or property (including cash) receivable upon such
reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the
holder of the Warrants would have received if such holder had exercised his, her or its Warrant(s) immediately prior to such event
(the “Alternative Issuance”); provided, however, that (i) if the holders of the Common Stock
were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such
merger or consolidation, then the kind and amount of securities, cash or other assets constituting the Alternative Issuance for
which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount received per share by
the holders of the Common Stock in such merger or consolidation that affirmatively make such election, and (ii) if a tender,
exchange or redemption offer shall have been made to and accepted by the holders of the Common Stock (other than a tender, exchange
or redemption offer made by the Company in connection with redemption rights held by stockholders of the Company as provided for in
the Company’s amended and restated certificate of incorporation or as a result of the redemption of shares of Common Stock by
the Company if a proposed initial Business Combination is presented to the stockholders of the Company for approval) under
circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group
(within the meaning of Rule 13d-5(b)(1) under the Exchange Act) of which such maker is a part, and together with any affiliate or
associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act) and any members of any such group of which any
such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act) securities
representing more than 50% of the aggregate voting power, including the power to vote on the election of directors of the Company,
of the issued and outstanding equity securities of the Company, and (for the avoidance of doubt) such tender offer results in a
change of control of the Company, the holder of a Warrant shall be entitled to receive as the Alternative Issuance, the highest
amount of cash, securities or other property to which such holder would actually have been entitled as a stockholder if such Warrant
holder had exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the shares
of Common Stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments (from and
after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in this Section
4; provided further that if less than 70% of the consideration receivable by the holders of the Common Stock in the
applicable event is payable in the form of stock in the successor entity that is listed for trading on a national securities
exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following
such event, and if the Registered Holder properly exercises the Warrant within thirty (30) days following the public disclosure of
the consummation of such applicable event by the Company pursuant to a Current Report on Form 8-K filed with the Commission, the
Warrant Price shall be reduced by an amount (in dollars) equal to the difference of (i) the Warrant Price in effect prior to such
reduction minus (ii) (A) the Per Share Consideration (as defined below) (but in no event less than zero) minus (B) the Black-Scholes
Warrant Value (as defined below). The “Black-Scholes Warrant Value” means (i) for Public Warrants, the
value of a Public Warrant immediately prior to the consummation of the applicable event based on the Black-Scholes Warrant Model for
a Capped American Call on Bloomberg Financial Markets (assuming zero dividends) (“Bloomberg”) and (ii) for
Private Placement Warrants and Sponsor Loan Warrants, the value of a Private Placement Warrant and Sponsor Loan Warrants
immediately prior to the consummation of the applicable event based on the Black-Scholes Warrant Model for an uncapped American Call
on Bloomberg, in each case, as calculated by an accounting, appraisal, investment banking firm or consultant of nationally
recognized standing that is, in the good faith judgment of the Board, qualified to make such calculation. “Per Share
Consideration” means (i) if the consideration paid to holders of the Common Stock consists exclusively of cash, the
amount of such cash per share of Common Stock, and (ii) in all other cases, the volume-weighted average price of the Common Stock
during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event. If any
reclassification or reorganization also results in a change in shares of Common Stock covered by subsection 4.1.1, then such
adjustment shall be made pursuant to subsection 4.1.1 or Sections 4.2, 4.3 and this Section 4.5. The
provisions of this Section 4.5 shall similarly apply to successive reclassifications, reorganizations, mergers or
consolidations, sales or other transfers. In no event shall the Warrant Price be reduced to less than the par value per share
issuable upon exercise of such Warrant.

 

    10

     

    

 

4.6             
Notices of Changes in Warrant. Upon every adjustment of the Warrant Price or the number of shares issuable upon exercise
of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting
from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a Warrant,
setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of
any event specified in Sections 4.1, 4.2, 4.3, 4.4, 4.5 or 4.9, the Company shall give written
notice of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register,
of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality
or validity of such event.

 

4.7             
No Fractional Shares. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue
fractional shares upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the holder of
any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon
such exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to such holder.

 

4.8             
Form of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this Section 4, and
Warrants issued after such adjustment may state the same Warrant Price and the same number of shares as is stated in the Warrants initially
issued pursuant to this Agreement; provided, however, that the Company may at any time in its sole discretion make any change
in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter
issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.

 

4.9              Other
Events. In case any event shall occur affecting the Company as to which none of the provisions of the preceding subsections of
this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to
(i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then, in each
such case, the Company shall appoint a firm of independent registered public accountants, investment banking or other appraisal firm
of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented by the
Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine that an adjustment is
necessary, the terms of such adjustment; provided, however, that under no circumstances shall the Warrants be adjusted
pursuant to this Section 4.9 as a result of any issuance of securities in connection with a Business Combination. The Company
shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion.

 

    11

     

    

 

5.            
Transfer and Exchange of Warrants.

 

5.1             
Registration of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon
the Warrant Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied
by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall
be issued and the old Warrant shall be cancelled by the Warrant Agent. In the case of certificated Warrants, the Warrants so cancelled
shall be delivered by the Warrant Agent to the Company from time to time upon request.

 

5.2              Procedure
for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or
transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered
Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that
except as otherwise provided herein or with respect to any Book-Entry Warrant, each Book-Entry Warrant may be transferred only in
whole and only to the Depositary, to another nominee of the Depositary, to a successor depository, or to a nominee of a successor
depository; provided further, however, that in the event that a Warrant surrendered for transfer bears a restrictive
legend (as in the case, initially, of the Private Placement Warrants and the Sponsor Warrants), the Warrant Agent shall not
cancel such Warrant and issue new Warrants in exchange thereof until the Warrant Agent has received an opinion of counsel for the
Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

 

5.3             
Fractional Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which shall
result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as part of the Units.

 

5.4             
Service Charges. No service charge shall be made for any exchange or registration of transfer of Warrants.

 

5.5             
Warrant Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance
with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company,
whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.

 

5.6              Transfer
of Warrants. Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only together with the Unit in
which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such Unit.
Furthermore, each transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants included in
such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6 shall have no effect on any transfer of Warrants
on and after the Detachment Date.

 

    12

     

    

 

6.            
Redemption.

 

6.1             
Redemption of Public Warrants. Not less than all of the outstanding Public Warrants may be redeemed for cash, at the option
of the Company, at any time during the Exercise Period, at the office of the Warrant Agent, upon notice to the Registered Holders of the
Public Warrants, as described in Section 6.2 below, at a Redemption Price of $0.01 per Public Warrant, provided that (a)
the Reference Value (as defined below) equals or exceeds $18.00 per share (subject to adjustment in compliance with Section 4 hereof)
and (b) either (i) there is an effective registration statement covering the issuance of the shares of Common Stock issuable upon
exercise of the Public Warrants, and a current prospectus relating thereto, available throughout the 30-day Redemption Period (as defined
in Section 6.2 below), or (ii) the Company has elected to require the exercise of the Public Warrants on a “cashless basis”
pursuant to subsection 3.3.1(b) hereof.

 

6.2             
Date Fixed for, and Notice of, Redemption; Redemption Price; Reference Value. In the event that the Company elects to redeem
the Public Warrants pursuant to Section 6.1, the Company shall fix a date for the redemption (the “Redemption
Date”). Notice of redemption shall be mailed by first class mail, postage prepaid, by the Company not less than 30 days
prior to the Redemption Date (the period lasting from such time until the Redemption Date, the “30-day Redemption Period”)
to the Registered Holders of the Public Warrants to be redeemed at their last addresses as they shall appear on the registration books.
Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the Registered Holder
received such notice. As used in this Agreement, (a) “Redemption Price” shall mean the price per Warrant
at which any Warrants are redeemed pursuant to Section 6.1 and (b) “Reference Value” shall mean
the last reported sale price of the shares of Common Stock for any twenty (20) trading days within the thirty (30) trading day period
ending on the third (3rd) trading day prior to the date on which notice of the redemption is given.

 

6.3             
Exercise After Notice of Redemption. The Public Warrants may be exercised for cash (or, if the Company has elected to require
exercise on a “cashless basis” in accordance with subsection 3.3.1(b) of this Agreement, on such “cashless basis”)
at any time after notice of redemption shall have been given by the Company pursuant to Section 6.2 hereof and prior to the Redemption
Date. In the event that the Company determines to require all holders of Warrants to exercise their Warrants on a “cashless basis”
pursuant to subsection 3.3.1(b), the notice of redemption shall contain the information necessary to calculate the number of shares
of Common Stock to be received upon exercise of the Warrants, including the “Fair Market Value” (as such term is defined in
subsection 3.3.1(b) hereof) in such case. On and after the Redemption Date, the record holder of the Public Warrants shall have
no further rights except to receive, upon surrender of the Public Warrants, the Redemption Price.

 

    13

     

    

 

7.           
 Other Provisions Relating to Rights of Holders of Warrants.

 

7.1             
No Rights as Stockholder. A Warrant does not entitle the Registered Holder thereof to any of the rights of a stockholder
of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights
to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of
the Company or any other matter.

 

7.2             
Lost, Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and
the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a
mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen,
mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the
allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

 

7.3             
Reservation of Shares of Common Stock. The Company shall at all times reserve and keep available a number of its authorized
but unissued shares of Common Stock that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant
to this Agreement.

 

7.4             
Registration of Shares of Common Stock; Cashless Exercise at Company’s Option.

 

7.4.1        Registration
of the shares of Common Stock. The Company agrees that as soon as practicable, but in no event later than fifteen (15) Business
Days after the closing of its initial Business Combination, it shall use its commercially reasonable efforts to file with the
Commission a registration statement for the registration, under the Securities Act, of the shares of Common Stock issuable upon
exercise of the Warrants. The Company shall use its commercially reasonable efforts to cause the same to become effective within
sixty (60) Business Days following the closing of its initial Business Combination and to maintain the effectiveness of such
registration statement, and a current prospectus relating thereto, until the expiration or redemption of the Warrants in accordance
with the provisions of this Agreement. If any such registration statement has not been declared effective by the sixtieth
(60th) Business Day following the closing of the Business Combination, holders of the Public Warrants shall have the
right, during the period beginning on the sixty-first (61st) Business Day after the closing of the Business Combination
and ending upon such registration statement being declared effective by the Commission, and during any other period when the Company
shall fail to have maintained an effective registration statement covering the issuance of the shares of Common Stock issuable upon
exercise of the Public Warrants, to exercise such Public Warrants on a “cashless basis,” by exchanging the Public
Warrants (in accordance with Section 3(a)(9) of the Securities Act or another exemption) for that number of shares of Common Stock
equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Public Warrants,
multiplied by the excess of the “Fair Market Value” (as defined below) less the Warrant Price by (y) the Fair Market
Value. Solely for purposes of this subsection 7.4.1, “Fair Market Value” shall mean the
volume-weighted average price of the shares of Common Stock as reported during the ten (10) trading day period ending on the trading
day prior to the date that notice of exercise is received by the Warrant Agent from the holder of such Warrants or its securities
broker or intermediary. The date that notice of “cashless exercise” is received by the Warrant Agent shall be
conclusively determined by the Warrant Agent. In connection with the “cashless exercise” of a Public Warrant, the
Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law
firm with securities law experience) stating that (i) the exercise of the Public Warrants on a “cashless basis” in
accordance with this subsection 7.4.1 is not required to be registered under the Securities Act and (ii) the shares of Common
Stock issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an
affiliate (as such term is defined in Rule 144 under the Securities Act) of the Company and, accordingly, shall not be required to
bear a restrictive legend. Except as provided in subsection 7.4.2, for the avoidance of doubt, unless and until all of the
Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations
under the first three sentences of this subsection 7.4.1.

 

    14

     

    

 

7.4.2       Cashless
Exercise at Company’s Option. If the shares of Common Stock are at the time of any exercise of a Public Warrant not listed
on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of
the Securities Act, the Company may, at its option, (i) require holders of Public Warrants who exercise Public Warrants to exercise such
Public Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act as described in subsection
7.4.1 and (ii) in the event the Company so elects, the Company shall (x) not be required to file or maintain in effect a registration
statement for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants, notwithstanding
anything in this Agreement to the contrary, and (y) use its commercially reasonable efforts to register or qualify for sale the shares
of Common Stock issuable upon exercise of the Public Warrant under applicable blue sky laws to the extent an exemption is not available.

 

7.4.3       Notwithstanding
the foregoing, if at any time pursuant to this Agreement the Public Warrants may be exercised on a “cashless basis” pursuant
to both (i) subsection 3.3.1(b) hereof and (ii) this Section 7.4, the cashless exercise of the Public Warrants must be
completed pursuant to the formula and terms set forth in subsection 3.3.1(b) hereof.

 

8.             Concerning
the Warrant Agent and Other Matters.

 

8.1           Payment
of Taxes. The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant
Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of the Warrants, but the Company shall not be
obligated to pay any transfer taxes in respect of the Warrants or such shares.

 

    15

     

    

 

8.2           Resignation,
Consolidation, or Merger of Warrant Agent.

 

8.2.1       Appointment
of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office
of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor
Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after
it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant (who shall, with
such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court
of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost. Any
successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation or other entity organized and existing
under the laws of the State of New York, in good standing and having its principal office in the United States of America, and authorized
under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment,
any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor
Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason
it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument
transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon
request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for
more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities,
duties, and obligations.

 

8.2.2       Notice
of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the
predecessor Warrant Agent and the Transfer Agent for the shares of Common Stock not later than the effective date of any such appointment.

 

8.2.3       Merger
or Consolidation of Warrant Agent. Any entity into which the Warrant Agent may be merged or with which it may be consolidated or
any entity resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent
under this Agreement without any further act.

 

8.3           Fees and Expenses of Warrant Agent.

 

8.3.1       Remuneration.
The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and shall, pursuant
to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably
incur in the execution of its duties hereunder.

 

8.3.2       Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed,
acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant
Agent for the carrying out or performing of the provisions of this Agreement.

 

    16

     

    

 

8.4           Liability of Warrant Agent.

 

8.4.1       Reliance
on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it necessary or
desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact
or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established
by a statement signed by the Chief Executive Officer, the Chief Financial Officer or the Chairman of the Board of the Company and delivered
to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to
the provisions of this Agreement.

 

8.4.2       Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct, fraud or bad
faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, out-of-pocket
costs and reasonable outside counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except
as a result of the Warrant Agent’s gross negligence, willful misconduct, fraud or bad faith.

 

8.4.3       Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect
to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any
breach by the Company of any covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall not be responsible
to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any
such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder
be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant
to this Agreement or any Warrant or as to whether any shares of Common Stock shall, when issued, be valid and fully paid and nonassessable.

 

8.5           Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the
same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants
exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of shares of
Common Stock through the exercise of the Warrants.

 

8.6           Waiver.
The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (“Claim”)
in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date
hereof, by and between the Company and Continental Stock Transfer & Trust Company as trustee thereunder) and hereby agrees not to
seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. The Warrant
Agent hereby waives any and all Claims against the Trust Account and any and all rights to seek access to the Trust Account.

 

    17

     

    

 

9.             Miscellaneous Provisions.

 

9.1           Successors.
All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to
the benefit of their respective successors and assigns.

 

9.2           Notices. Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the
holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by
certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another
address is filed in writing by the Company with the Warrant Agent), as follows:

 

Arbor Rapha Capital Bioholdings Corp. I

555 Earle Ovington Blvd. Suite 900

Uniondale, New York 11553

Attention: Ivan Kaufman

 

in each case, with copies to:

 

Skadden, Arps, Slate, Meagher & Flom LLP

One Manhattan West

New York, NY 10001

Attn: David J. Goldschmidt, Esq.

Email: david.goldschmidt@skadden.com

 

and

 

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas

New York, NY 10105

Attn: Stuart Neuhauser, Esq.

Email: sneuhauser@egsllp.com

 

Any notice, statement or demand authorized by this Agreement to be
given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be sufficiently given when so delivered
if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice,
postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with the Company), as follows:

 

Continental Stock Transfer & Trust Company

One State Street, 30th Floor

New York, NY 10004

Attention: Compliance Department

 

    18

     

    

 

9.3           Applicable
Law and Exclusive Forum. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed
in all respects by the laws of the State of New York. Subject to applicable law, the Company hereby agrees that any action,
proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts
of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such
jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. The Company hereby waives
any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Notwithstanding the foregoing,
the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any
other claim for which the federal district courts of the United States of America are the sole and exclusive forum.

 

Any person or entity purchasing or otherwise acquiring
any interest in the Warrants shall be deemed to have notice of and to have consented to the forum provisions in this Section 9.3.
If any action, the subject matter of which is within the scope of the forum provisions above, is filed in a court other than a court located
within the State of New York or the United States District Court for the Southern District of New York (a “foreign action”)
in the name of any warrant holder, such warrant holder shall be deemed to have consented to: (x) the personal jurisdiction of the state
and federal courts located within the State of New York or the United States District Court for the Southern District of New York in connection
with any action brought in any such court to enforce the forum provisions (an “enforcement action”), and (y)
having service of process made upon such warrant holder in any such enforcement action by service upon such warrant holder’s counsel
in the foreign action as agent for such warrant holder.

 

9.4           Persons
Having Rights under this Agreement. Nothing in this Agreement shall be construed to confer upon, or give to, any person, corporation
or other entity other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by reason
of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations,
promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors
and assigns and of the Registered Holders of the Warrants.

 

9.5           Examination
of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent
in the United States of America, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder
to submit such holder’s Warrant for inspection by the Warrant Agent.

 

9.6           Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts
shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

9.7           Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not
affect the interpretation thereof.

 

    19

     

    

 

9.8           Amendments.
This Agreement may be amended by the parties hereto without the consent of any Registered Holder for the purpose of (i) curing any
ambiguity or correcting any mistake, including conforming the provisions hereof to the description of the terms of the Warrants and
this Agreement set forth in the Prospectus, or defective provision contained herein, (ii) removing or reducing the Company’s
ability to redeem the Public Warrants, or (iii) adding or changing any provisions with respect to matters or questions arising under
this Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the rights of the
Registered Holders under this Agreement in any material respect. This Agreement may be amended by the parties hereto with the vote
or written consent of the Registered Holders of at least 50% of the then-outstanding Public Warrants, Sponsor Loan Warrants and
Private Placement Warrants, voting together as a single class, to allow for the Warrants to be or continue to be, as applicable,
classified as equity in the Company’s financial statements. Subject to the final proviso contained in each of Sections 3.1
and 3.2, all other modifications or amendments, including any modification or amendment to increase the Warrant Price or shorten
the Exercise Period, (a) with respect to the terms of the Public Warrants or any provision of this Agreement with respect to the
Public Warrants, shall require the vote or written consent of the Registered Holders of at least 50% of the then outstanding Public
Warrants and (b) with respect to the terms of the Private Placement Warrants, Sponsor Loan Warrants, or any provision of this
Agreement with respect to the Private Placement Warrants or Sponsor Loan Warrants shall require the vote or written consent of at
least 50% of the then outstanding Private Placement Warrants and Sponsor Loan Warrants. Notwithstanding the foregoing, the Company
may lower the Warrant Price or extend the duration of the Exercise Period pursuant to and in accordance with Sections 3.1 and 3.2,
respectively, without the consent of the Registered Holders.

 

9.9           Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to
such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

Exhibit A Form of Warrant Certificate

Exhibit B Legend — Private Placement
Warrants and Sponsor Loan Warrants

 

    20

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be duly executed as of the date first above written.

 

	 	ARBOR
    RAPHA CAPITAL BIOHOLDINGS CORP. I
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title: Authorized Signatory
	 	 
	 	 
	 	CONTINENTAL
    STOCK TRANSFER & TRUST COMPANY, as Warrant Agent
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature Page to Warrant
Agreement]

 

     

     

    

 

EXHIBIT A

 

 

[FACE]

 

Number

 

Warrants

 

THIS WARRANT SHALL BE VOID IF NOT EXERCISED
PRIOR TO

THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR

IN THE WARRANT AGREEMENT DESCRIBED BELOW

 

Arbor Rapha Capital Bioholdings Corp. I

Incorporated Under the Laws of the State of
Delaware

 

CUSIP [●]

Warrant Certificate

 

This Warrant Certificate certifies that
                   , or registered assigns, is
the registered holder of                   warrant(s)
(the “Warrants” and each, a “Warrant”) to purchase shares of Class A common stock,
$0.0001 par value (“Common Stock”), of Arbor Rapha Capital Bioholdings Corp. I, a Delaware corporation (the
 “Company”). Each Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement
referred to below, to receive from the Company that number of fully paid and nonassessable shares of Common Stock as set forth below,
at the exercise price (the “Exercise Price”) as determined pursuant to the Warrant Agreement, payable in lawful
money (or through “cashless exercise” as provided for in the Warrant Agreement) of the United States of America
upon surrender of this Warrant Certificate and payment of the Exercise Price at the office or agency of the Warrant Agent referred to
below, subject to the conditions set forth herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not
defined herein shall have the meanings given to them in the Warrant Agreement.

 

Each whole Warrant is initially exercisable for
one fully paid and non-assessable share of Common Stock. Fractional shares shall not be issued upon exercise of any Warrant. If, upon
the exercise of Warrants, a holder would be entitled to receive a fractional interest in a share of Common Stock, the Company shall, upon
exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to the Warrant holder. The number of
shares of Common Stock issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events as set forth
in the Warrant Agreement.

 

The initial Exercise Price per one share of Common
Stock for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment upon the occurrence of certain events
as set forth in the Warrant Agreement.

 

Subject to the conditions
set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised by
the end of such Exercise Period, such Warrants shall become void. The Warrants may be redeemed, subject to certain conditions, as
set forth in the Warrant Agreement.

 

     

     

    

 

Reference is hereby made to the further provisions
of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have the same effect as
though fully set forth at this place.

 

This Warrant Certificate shall not be valid unless
countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.

 

This Warrant Certificate shall be governed by and
construed in accordance with the internal laws of the State of New York.

 

	 	ARBOR
    RAPHA CAPITAL BIOHOLDINGS CORP. I
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title: Authorized Signatory
	 	 
	 	 
	 	CONTINENTAL
    STOCK TRANSFER & TRUST COMPANY, AS WARRANT AGENT
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

     

     

    

 

[Form of Warrant Certificate]

 

[Reverse]

 

The Warrants evidenced by this Warrant Certificate
are part of a duly authorized issue of Warrants entitling the holder on exercise to receive                      
shares of Common Stock and are issued or to be issued pursuant to a Warrant Agreement dated as of [●], 2021 (the “Warrant
Agreement”), duly executed and delivered by the Company to Continental Stock Transfer & Trust Company, a New York corporation,
as warrant agent (the “Warrant Agent”), which Warrant Agreement is hereby incorporated by reference in and made
a part of this instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities
thereunder of the Warrant Agent, the Company and the holders (the words “holders” or “holder”
meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy of the Warrant Agreement may be obtained by
the holder hereof upon written request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have
the meanings given to them in the Warrant Agreement.

 

Warrants may be exercised at any time during the
Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate may exercise them by
surrendering this Warrant Certificate, with the form of Election to Purchase set forth hereon properly completed and executed, together
with payment of the Exercise Price as specified in the Warrant Agreement (or through “cashless exercise” as
provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon any exercise
of Warrants evidenced hereby, the number of Warrants exercised shall be less than the total number of Warrants evidenced hereby, there
shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not exercised.

 

Notwithstanding anything else in this Warrant Certificate
or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement covering the issuance
of the shares of Common Stock to be issued upon exercise is effective under the Securities Act and (ii) a prospectus thereunder relating
to the shares of Common Stock is current, except through “cashless exercise” as provided for in the Warrant
Agreement or if another exemption from registration is available.

 

The Warrant Agreement provides that upon the occurrence
of certain events the number of shares of Common Stock issuable upon exercise of the Warrants set forth on the face hereof may, subject
to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive a fractional interest
in a share of Common Stock, the Company shall, upon exercise, round down to the nearest whole number of shares of Common Stock to be issued
to the holder of the Warrant.

 

Warrant Certificates, when
surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by legal
representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in
the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like
tenor evidencing in the aggregate a like number of Warrants.

 

     

     

    

 

Upon due presentation for registration of transfer
of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or Warrant Certificates of like tenor and evidencing
in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this Warrant Certificate, subject to the
limitations provided in the Warrant Agreement, without charge except for any tax or other governmental charge imposed in connection therewith.

 

The Company and the Warrant Agent may deem and
treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation of ownership
or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s) hereof, and for
all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. Neither the Warrants
nor this Warrant Certificate entitles any holder hereof to any rights of a stockholder of the Company.

 

     

     

    

 

Election to Purchase

(To Be Executed Upon Exercise of Warrant)

 

The undersigned hereby irrevocably elects to exercise
the right, represented by this Warrant Certificate, to receive            shares of
Common Stock and herewith tenders payment for such shares of Common Stock to the order of Arbor Rapha Capital Bioholdings Corp. I (the
“Company”) in the amount of $           in accordance with
the terms hereof. The undersigned requests that a certificate for such shares of Common Stock be registered in the name of                           ,
whose address is            and that such shares of Common Stock be delivered to           
       whose address is                .
If said number of shares of Common Stock is less than all of the shares of Common Stock purchasable hereunder, the undersigned requests
that a new Warrant Certificate representing the remaining balance of such shares of Common Stock be registered in the name of                ,
whose address is                   and that such Warrant Certificate
be delivered to                , whose address is                .

 

In the event that the Warrant is a Public Warrant
that is to be exercised on a “cashless” basis as required by the Company pursuant to Section 6.1 of the Warrant Agreement,
the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(b)
of the Warrant Agreement.

 

In the event that the
Warrant is a Private Placement Warrant or Sponsor Loan Warrant that is to be exercised on a “cashless” basis pursuant to subsection
3.3.1(c) of the Warrant Agreement, the number of shares of Common Stock that this Warrant is exercisable for shall be determined
in accordance with subsection 3.3.1(c) of the Warrant Agreement.

 

In the event that the Warrant is a Public Warrant
that is to be exercised on a “cashless” basis pursuant to Section 7.4 of the Warrant Agreement, the number of shares
of Common Stock that this Warrant is exercisable for shall be determined in accordance with Section 7.4 of the Warrant Agreement.

 

In the event that the Warrant may be exercised,
to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of shares of Common Stock that this Warrant is
exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless exercise
and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right, represented
by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive shares of Common Stock. If
said number of shares of Common Stock is less than all of the shares of Common Stock purchasable hereunder (after giving effect to the
cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such shares of Common
Stock be registered in the name of                , whose address
is                   and that such Warrant Certificate be delivered
to                , whose address is                .

 

[Signature Page Follows]

 

     

     

    

 

	Date:
                         , 20	 
	 	(Signature)
	 	 
	 	(Address)
	 	 
	 	 
	 	(Tax
    Identification Number)

 

	Signature Guaranteed:	 
	 	 
	 	 

 

THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE
GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE
MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED).

 

     

     

    

 

EXHIBIT B

 

LEGEND

 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS
AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE LETTER AGREEMENT (THE “LETTER AGREEMENT”)
BY AND BETWEEN ARBOR RAPHA CAPITAL BIOHOLDINGS CORP. I (THE “COMPANY”) AND EACH OF ARBOR RAPHA CAPITAL LLC AND THE OTHER PARTIES
THERETO, THE SECURITIES REPRESENTED HEREBY MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON
WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN THE RECITALS OF THE WARRANT AGREEMENT REFERRED TO HEREIN)
EXCEPT TO A PERMITTED TRANSFEREE (AS DESCRIBED IN SECTION 7(D) OF THE LETTER AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT
TO SUCH TRANSFER PROVISIONS.

 

SECURITIES EVIDENCED HEREBY AND SHARES OF CLASS A COMMON STOCK OF THE
COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED
BY THE COMPANY.

 

NO.                                  WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]